Search Results for: YBX1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel LCK LCK proto-oncogene, Src family tyrosine kinase
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Nef and signal transduction
  • Nef Mediated CD4 Down-regulation
  • Downstream TCR signaling
  • Phosphorylation of CD3 and TCR zeta chains
  • Translocation of ZAP-70 to Immunological synapse
  • Generation of second messenger molecules
  • PECAM1 interactions
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • DAP12 signaling
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • CTLA4 inhibitory signaling
  • PD-1 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Interleukin-2 signaling
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • FLT3 signaling through SRC family kinases
  • Dasatinib
  • AP-22408
  • Staurosporine
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • {4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE
  • 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE
  • N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
  • N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
  • N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine
  • Ponatinib
  • Nintedanib
  • Fostamatinib
  • Zanubrutinib
  • Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
Novel PTPRF protein tyrosine phosphatase receptor type F
  • Receptor-type tyrosine-protein phosphatases
  • Synaptic adhesion-like molecules
ACTA2 actin alpha 2, smooth muscle
  • Smooth Muscle Contraction
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Phenethyl Isothiocyanate
  • Familial thoracic aortic aneurysm and dissection (TAAD); Aortic aneurysm familial thoracic type (AAT)
AKT1 AKT serine/threonine kinase 1
  • Activation of BAD and translocation to mitochondria
  • PIP3 activates AKT signaling
  • PIP3 activates AKT signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • MTOR signalling
  • AKT phosphorylates targets in the cytosol
  • AKT phosphorylates targets in the cytosol
  • AKT phosphorylates targets in the nucleus
  • Negative regulation of the PI3K/AKT network
  • eNOS activation
  • AKT-mediated inactivation of FOXO1A
  • Integrin signaling
  • Deactivation of the beta-catenin transactivating complex
  • CD28 dependent PI3K/Akt signaling
  • CTLA4 inhibitory signaling
  • G beta:gamma signalling through PI3Kgamma
  • Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA
  • KSRP (KHSRP) binds and destabilizes mRNA
  • VEGFR2 mediated vascular permeability
  • TP53 Regulates Metabolic Genes
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Interleukin-4 and Interleukin-13 signaling
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Association with Co-factors
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Cyclin E associated events during G1/S transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
  • RAB GEFs exchange GTP for GDP on RABs
  • RUNX2 regulates genes involved in cell migration
  • Regulation of PTEN stability and activity
  • Extra-nuclear estrogen signaling
  • Negative regulation of NOTCH4 signaling
  • FLT3 Signaling
  • Regulation of localization of FOXO transcription factors
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • ATP
  • Arsenic trioxide
  • Genistein
  • Inositol 1,3,4,5-Tetrakisphosphate
  • Resveratrol
  • Archexin
  • Enzastaurin
  • Perifosine
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • PTEN hamartoma tumor syndrome (PHTS), including: Cowden syndrome; Bannayan-Riley-Ruvalcaba syndrome; Proteus syndrome; Proteus-like syndrome
ANKRD2 ankyrin repeat domain 2
APBB1 amyloid beta precursor protein binding family B member 1
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
CALM1 calmodulin 1
  • CaMK IV-mediated phosphorylation of CREB
  • CaMK IV-mediated phosphorylation of CREB
  • Calmodulin induced events
  • Cam-PDE 1 activation
  • CaM pathway
  • Platelet degranulation
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • PKA activation
  • DARPP-32 events
  • Synthesis of IP3 and IP4 in the cytosol
  • Calcineurin activates NFAT
  • Calcineurin activates NFAT
  • eNOS activation
  • Transcriptional activation of mitochondrial biogenesis
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Stimuli-sensing channels
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • Ca2+ pathway
  • Reduction of cytosolic Ca++ levels
  • Sodium/Calcium exchangers
  • Unblocking of NMDA receptors, glutamate binding and activation
  • CREB1 phosphorylation through the activation of Adenylate Cyclase
  • CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde
  • CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde
  • Ras activation upon Ca2+ influx through NMDA receptor
  • Smooth Muscle Contraction
  • Smooth Muscle Contraction
  • Activation of Ca-permeable Kainate Receptor
  • Uptake and function of anthrax toxins
  • VEGFR2 mediated vascular permeability
  • VEGFR2 mediated cell proliferation
  • Phase 0 - rapid depolarisation
  • Ion homeostasis
  • CLEC7A (Dectin-1) induces NFAT activation
  • CLEC7A (Dectin-1) induces NFAT activation
  • RHO GTPases activate IQGAPs
  • RHO GTPases activate PAKs
  • RHO GTPases activate PAKs
  • RAF activation
  • RAF/MAP kinase cascade
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Glycogen breakdown (glycogenolysis)
  • Glycogen breakdown (glycogenolysis)
  • Protein methylation
  • Extra-nuclear estrogen signaling
  • Loss of phosphorylation of MECP2 at T308
  • Regulation of MECP2 expression and activity
  • Ion transport by P-type ATPases
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Activation of RAC1 downstream of NMDARs
  • Activation of RAC1 downstream of NMDARs
  • Activation of AMPK downstream of NMDARs
  • Long-term potentiation
  • Long-term potentiation
  • RAS processing
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated IL10 synthesis
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Chlorpromazine
  • Cinchocaine
  • Nicardipine
  • Fluphenazine
  • Isoflurane
  • Trifluoperazine
  • Loperamide
  • Perphenazine
  • Phenoxybenzamine
  • Felodipine
  • Melatonin
  • Promethazine
  • Pimozide
  • Nifedipine
  • Bepridil
  • Calcium
  • Aprindine
  • Deacetoxyvinzolidine
  • tert-butanol
  • Trimethyllysine
  • N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide
  • Prenylamine
  • Flunarizine
  • (3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE
  • Myristic acid
  • Calcium citrate
  • Calcium citrate
  • Calcium citrate
  • Calcium Phosphate
  • Calcium Phosphate
  • Calcium Phosphate
  • Calcium levulinate
  • Calcium phosphate dihydrate
  • Calcium phosphate dihydrate
  • Calcium phosphate dihydrate
CASP8 caspase 8
  • Apoptotic cleavage of cellular proteins
  • Caspase activation via Death Receptors in the presence of ligand
  • NOD1/2 Signaling Pathway
  • TRIF-mediated programmed cell death
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • TNFR1-induced proapoptotic signaling
  • Regulation of TNFR1 signaling
  • CLEC7A/inflammasome pathway
  • Regulation of necroptotic cell death
  • Dimerization of procaspase-8
  • Activation, myristolyation of BID and translocation to mitochondria
  • Apoptotic execution phase
  • FasL/ CD95L signaling
  • TRAIL signaling
  • TLR3-mediated TICAM1-dependent programmed cell death
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • Microbial modulation of RIPK1-mediated regulated necrosis
  • Defective RIPK1-mediated regulated necrosis
  • Bryostatin 1
  • Bardoxolone
  • Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
CSNK2A1 casein kinase 2 alpha 1
  • Synthesis of PC
  • WNT mediated activation of DVL
  • Condensation of Prometaphase Chromosomes
  • Signal transduction by L1
  • Regulation of TP53 Activity through Phosphorylation
  • Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding
  • Receptor Mediated Mitophagy
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
  • Regulation of PTEN stability and activity
  • ATP
  • (5-hydroxyindolo[1,2-a]quinazolin-7-yl)acetic acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Quercetin
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • Emodin
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • Dichlororibofuranosylbenzimidazole
  • Quinalizarin
  • Ellagic acid
  • Fostamatinib
CTCF CCCTC-binding factor
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
DUX4 double homeobox 4
FBXO33 F-box protein 33
FMR1 FMRP translational regulator 1
  • Premature ovarian failure
  • Fragile X Syndrome, including: Fragile X Syndrome (FXS); Fragile X tremor/ataxia syndrome (FXTAS)
FUS FUS RNA binding protein
  • mRNA Splicing - Major Pathway
  • Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
  • Myxoid liposarcoma
GSK3B glycogen synthase kinase 3 beta
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • AKT phosphorylates targets in the cytosol
  • Regulation of HSF1-mediated heat shock response
  • CRMPs in Sema3A signaling
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • B-WICH complex positively regulates rRNA expression
  • Signaling by GSK3beta mutants
  • S33 mutants of beta-catenin aren't phosphorylated
  • S37 mutants of beta-catenin aren't phosphorylated
  • S45 mutants of beta-catenin aren't phosphorylated
  • T41 mutants of beta-catenin aren't phosphorylated
  • APC truncation mutants have impaired AXIN binding
  • AXIN missense mutants destabilize the destruction complex
  • Truncations of AMER1 destabilize the destruction complex
  • Degradation of GLI2 by the proteasome
  • GLI3 is processed to GLI3R by the proteasome
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Ubiquitin-dependent degradation of Cyclin D
  • Regulation of RUNX2 expression and activity
  • Replication of the SARS-CoV-1 genome
  • Maturation of nucleoprotein
  • Maturation of nucleoprotein
  • Maturation of nucleoprotein
  • Replication of the SARS-CoV-2 genome
  • Lithium cation
  • 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
  • SB-409513
  • AR-AO-14418
  • Staurosporine
  • Indirubin-3'-monoxime
  • 6-bromoindirubin-3'-oxime
  • Alsterpaullone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
  • 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
  • (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one
  • N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
  • 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
  • ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
  • (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
  • Fostamatinib
  • Tideglusib
  • Lithium citrate
  • Lithium succinate
  • Lithium carbonate
H1-2 H1.2 linker histone, cluster member
  • Apoptosis induced DNA fragmentation
  • Formation of Senescence-Associated Heterochromatin Foci (SAHF)
HABP4 hyaluronan binding protein 4
  • Platelet degranulation
  • Hyaluronic acid
HLA-C major histocompatibility complex, class I, C
  • ER-Phagosome pathway
  • ER-Phagosome pathway
  • Endosomal/Vacuolar pathway
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Neutrophil degranulation
  • Interferon gamma signaling
  • Interferon alpha/beta signaling
  • Antigen Presentation: Folding, assembly and peptide loading of class I MHC
  • Antigen Presentation: Folding, assembly and peptide loading of class I MHC
HNRNPD heterogeneous nuclear ribonucleoprotein D
  • mRNA Splicing - Major Pathway
  • Processing of Capped Intron-Containing Pre-mRNA
  • Artenimol
HNRNPK heterogeneous nuclear ribonucleoprotein K
  • SUMOylation of RNA binding proteins
  • mRNA Splicing - Major Pathway
  • Processing of Capped Intron-Containing Pre-mRNA
  • HCMV Late Events
  • Artenimol
  • Phenethyl Isothiocyanate

Page 1 out of 6 pages